Factors predicting response to antiretroviral regimens with a protease inhibitor in HIV-infected subjects;Facteurs prédictifs de réponse virologique à un traitement antirétroviral avec inhibiteur de protése au cours de l'infection à VIH

Presse Medicale

Volumn 30, Issue 1, 2001, Pages 5-10

  Meynard, J L ^a   Guiguet, M ^a   Rachline, A ^a   Boukli, N ^a   Bollens, D ^a   Gentil, C ^a   Frottier, J ^a   Morand Joubert, L ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; DIAGNOSTIC TEST; DRUG MIXTURE; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS DIAGNOSIS; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 0035852453     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. HIV-1-dynamics in viva: Virion clearance rate, infected cell life span, and viral generation time
2. Plasma viral load and CD4+ lymphocytes as predictive markers of HIV-1 infection
3. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study
4. The duration of viral suppression during protease inhibitor therapy for HIV infection is predicted by plasma HIV-1 RNA at the nadir
5. Hidden dangers of incompletely suppressive antiretroviral therapy
6. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
7. Treatment with indinavir, zidovudine and lamuvidine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
8. A control trial of two nucleoside analosues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cells counts of 200 per cubic millimeter or less
9. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
10. Declining morbidity and mortality among patients with adavanced human immubnodeficiency virus infection
11. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
12. Clinical progression and virological failure or highly active antiretroviral therapy in HIV1 patients: A prospective cohort study
13. Virologic treatment failure of protease inhibitor therapy in an unselected cohort of HIV infected patients
14. Predictors of long term response to protease inhibitor therapy in a cohort of HIV infected patients
15. Stratégies d'utilisation des antiretroviraux dans l'infection par le VIH: Rapport
16. Ordinal regression models for epidermiologic data
17. Combination therapy containing ritonavir plus saquinavir has superior short -term antiretroviral efficacy: A randomized trial
18. Impact of drug resistance mutations on virologic response to salvage therapy